Compositions in homogenised powder form consisting of hydroxypropyl methylcellulose particles, and at least one chemical signalling agent in particle form, and optionally a biologically active agent, wherein the homogenised powder comprises particles having a mean particle diameter of ≥20 μm to ≤500 μmm uses and kits therefor.

The teachings provided herein generally relate to enhanced antivirulents that inactivate antibiotic-resistant bacteria as opposed to relying on an antimicrobial killing of the bacteria, and the antivirulents are safe for oral administration. As such, the systems taught herein are valuable methods that provide an alternate pathway for treating a subject having an antibiotic-resistant bacterial infection.

The teachings provided herein generally relate to enhanced antivirulents that inactivate antibiotic-resistant bacteria as opposed to relying on an antimicrobial killing of the bacteria, and the antivirulents are safe for oral administration. As such, the systems taught herein are valuable methods that provide an alternate pathway for treating a subject having an antibiotic-resistant bacterial infection.

A Camellia extract obtained by extracting by ultrasound a powder of Camellia japonica flowers, the powder being impregnated with a fatty substance or a mixture of fatty substances, with a hydroalcoholic solvent, and a cosmetic composition including such an extract having in particular a soothing effect for the skin. Also, a non-therapeutic use thereof for soothing the skin.

The invention relates to an extract of Ashwagandha that exhibit enhanced bioactivity and bioavailability comprising of enriched withanolide glycosides and saponins; with negligible amount of alkaloids, withanolide aglycones and oligosaccharides. The extract as disclosed prepared from root, stems, leaves and whole plant of Ashwagandha further shows improved immunomodulatory activity, anti-inflammatory activity, anti stress activity, antidiabetic activity and sleep quality. The disclosure also provides a method of improving bioactivity of withanolide glycosides even at lower doses, by the administration of an enteric coated formulation of extract of Ashwagandha to humans. The enteric coating protects the composition from hydrolysis in the acidic environment of the stomach to release the withanolide glycoside in neutral/alkaline pH in gastrointestinal tract (GIT) thus enhancing the absorption. Further the process of preparation of the extract of Ashwagandha enriched with withanolide glycosides and saponins are disclosed along with various formulations.

The invention relates to an extract of Ashwagandha that exhibit enhanced bioactivity and bioavailability comprising of enriched withanolide glycosides and saponins; with negligible amount of alkaloids, withanolide aglycones and oligosaccharides. The extract as disclosed prepared from root, stems, leaves and whole plant of Ashwagandha further shows improved immunomodulatory activity, anti-inflammatory activity, anti stress activity, antidiabetic activity and sleep quality. The disclosure also provides a method of improving bioactivity of withanolide glycosides even at lower doses, by the administration of an enteric coated formulation of extract of Ashwagandha to humans. The enteric coating protects the composition from hydrolysis in the acidic environment of the stomach to release the withanolide glycoside in neutral/alkaline pH in gastrointestinal tract (GIT) thus enhancing the absorption. Further the process of preparation of the extract of Ashwagandha enriched with withanolide glycosides and saponins are disclosed along with various formulations.

The present invention relates to anti-cancer agents comprising 1,2,4-trioxane compounds and anti-cancer agents comprising combinations comprising 1,2,4-trioxane compounds and chlorogenic acids. The invention further provides pharmaceutical compositions comprising such anti-cancer agents, kits comprising the same as well as methods and treatment regimens of using the aforementioned anti-cancer agents, pharmaceutical compositions and kits in the treatment and prevention of cancer and for prolonging survival of subjects having cancer, in particular ovarian cancer or lung cancer.

The present invention relates to anti-cancer agents comprising 1,2,4-trioxane compounds and anti-cancer agents comprising combinations comprising 1,2,4-trioxane compounds and chlorogenic acids. The invention further provides pharmaceutical compositions comprising such anti-cancer agents, kits comprising the same as well as methods and treatment regimens of using the aforementioned anti-cancer agents, pharmaceutical compositions and kits in the treatment and prevention of cancer and for prolonging survival of subjects having cancer, in particular ovarian cancer or lung cancer.

The present invention relates to anti-cancer agents comprising 1,2,4-trioxane compounds and anti-cancer agents comprising combinations comprising 1,2,4-trioxane compounds and chlorogenic acids. The invention further provides pharmaceutical compositions comprising such anti-cancer agents, kits comprising the same as well as methods and treatment regimens of using the aforementioned anti-cancer agents, pharmaceutical compositions and kits in the treatment and prevention of cancer and for prolonging survival of subjects having cancer, in particular ovarian cancer or lung cancer.

A pharmaceutical composition containing dry powder of pine (Pinus) needles and dry peels and pits of grapes extract and pharmaceutically acceptable additive, dry extracts of ginger (Zingiber officinale), turmeric (Curcuma longa), white peony (Paeonia), Rhodiola Rosea (Rhodiola Rosea), apricot (Prunus) seed, oyster mushroom (Pleurotus ostreatus), green tea (Camellia sinensis), Ginkgo Biloba (Ginkgo biloba), white pepper, pomegranate (Punica granatum) pulp, medlar (Mespilus germanica), dry powder of pomegranate (Punica granatum) juice and folic acid, in the following ratio of the components in weight % (w %):

TABLE-US-00001 dry powder of pine needles and dry peels and pits of grapes extract and pharmaceutically acceptable additive 6-24 dry extract of ginger 6-25 dry extract of turmeric 5-24 dry extract of white peony 2-20 dry extract of Rhodiola Rosea 2-20 dry extract of apricot seed 5-20 dry extract of oyster mushroom 10-34 dry extract of green tea 12-35 dry extract of Ginkgo Biloba 2-25 dry extract of white pepper 1-15 dry extract of pomegranate pulp 2-20 extract of medlar 2-20 dry powder of pomegranate juice 2-25 folic acid 3-30